Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, individual dose titration study to evaluate safety, tolerability and pharmacokinetics of riociguat in children from 6 to less than 18 years of age with pulmonary arterial hypertension (PAH)

Next Previous
X
Search
Trial Profile

Open-label, individual dose titration study to evaluate safety, tolerability and pharmacokinetics of riociguat in children from 6 to less than 18 years of age with pulmonary arterial hypertension (PAH)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Riociguat (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Registrational
  • Acronyms PATENT-CHILD
  • Sponsors Bayer HealthCare; Bayer Yakuhin

    • Most Recent Events

    • 30 Aug 2024 Planned End Date changed from 27 Jan 2031 to 31 Jul 2026.
    • 29 Aug 2023 This trial has been completed in Poland according to European Clinical Trials Database record.
    • 30 May 2022 Planned End Date changed from 25 Nov 2031 to 27 Jan 2031.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top